Denali Therapeutics Inc (DNLI) Stock
NASDAQ · DNLI
19.72
Fundamentals
Market cap
$3.15B
Price / Earnings ratio
-6.3x
Price / Sales ratio
892.8x
Price / Book ratio
3.9x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Denali Therapeutics Inc
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
SectorHealthcare
IndustryBiotechnology
Employees503
CEODr. Ryan J. Watts Ph.D.
IPO DateDec 8, 2017
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, President, CEO & Director | 1976 |
| Dr. Alexander O. Schuth M.D., Ph.D. | Co-Founder, CFO, COO & Secretary | 1973 |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer | — |
| Mr. Joe Lewcock Ph.D. | Chief Scientific Officer | — |
| Mr. Chris Walsh J.D. | General Counsel | — |
| Ms. Cindy Dunkle | Chief People Officer | — |
| Ms. Katie Peng M.B.A. | Chief Commercial Officer | 1971 |
| Mr. Peter Chin M.D. | Acting Chief Medical Officer & Head of Development | 1968 |
Fundamentals
Valuation
Market cap$3.15B
Price-to-sales ratio892.81
Price-to-book value3.85
Price-earnings ratio-6.30
Return on Equity-52.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.84
Income Statement
Average volume1,247,906
EBITDA$-492.55M
1 year high (52w)$27.30
1 year low (52w)$12.58
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



